US border & customs scrutiny rises as pharmaceutical tariff changes hit North American sourcing

Key Takeaways

• US pharmaceutical tariffs trigger higher CBSA exam rates and origin verification requests on Canadian imports under HS chapter 30.
• CUSMA origin claims for generics sourced with non-North American APIs are now audit targets—review certificates before the next CAD filing.
• Cold chain temperature logs are part of CARM Phase 2 Release 3 electronic files; reefer deviations can trigger Health Canada holds.
• Four-year duty drawback window exists for over-paid MFN duties, but requires origin documentation filed in CARM at time of original import.

What the new US tariff environment means at the Canadian border

The Trump administration’s announced tariffs on generic pharmaceuticals are creating immediate compliance friction for Canadian importers who source active pharmaceutical ingredients (APIs) or finished products from US suppliers, or who route shipments through US transshipment hubs. Even if your final destination is Canada and you’ve been filing CUSMA origin claims for years, CBSA is now flagging pharmaceutical imports under HS chapter 30 for origin verification at higher rates than we saw in Q1.

US policy changes don’t stop at the 49th parallel. When the US imposes tariffs on a product category, two things happen at the us border & customs crossing into Canada.

US transshipment becomes costlier. If your pharmaceutical shipment originates in India or China, lands at a US port, and then trucks north, you’re now dealing with US duties, Canadian duties, and the paperwork friction of proving the goods didn’t originate in the US under CUSMA rules. That’s a CBSA verification waiting to happen.

CBSA risk-scoring tightens. CBSA’s Targeting and Intelligence Division watches US trade actions closely. A new US tariff on generics signals a higher-risk commodity class, so expect more exams, more origin questionnaires, and more requests for manufacturing affidavits on your Commercial Accounting Declaration filings in the CARM Client Portal.

We’ve seen this pattern before with steel, aluminum, and softwood lumber. Pharmaceutical imports are next.

CUSMA origin and HS classification pressure points

Most generic pharmaceutical imports fall under HS headings 3003 or 3004 (medicaments in dosage form or bulk). Under CUSMA, these products qualify for preferential duty treatment if they meet regional value content thresholds and tariff-shift rules detailed in CBSA’s D11-4-2 memorandum on CUSMA origin.

The problem: APIs sourced from non-CUSMA countries (India, China, EU) often fail the tariff-shift test even if final formulation happens in the US or Mexico. If your US supplier hasn’t updated their CUSMA origin certificate to reflect post-tariff supply chain changes, your CAD filing is sitting on a compliance time bomb.

CBSA has 30 days from the date of a CUSMA origin claim to issue a verification request. If the certificate falls apart under scrutiny, you’re looking at retroactive MFN duty, interest, and potential AMPS penalties if the claim was negligent. We’ve seen AMPS Level 1 penalties start at $3,500 per contravention for insufficient due diligence on origin claims.

CARM filing and cold chain logistics

Pharmaceutical imports also carry OGD (Other Government Department) complexity. Health Canada’s establishment licensing requirements under the Food and Drugs Act mean your CAD in the CARM Client Portal must include the correct Drug Identification Number (DIN) or Natural Product Number (NPN) before CBSA releases the shipment. Miss that field, and your release prior to payment (RPP) bond doesn’t help. The goods sit at the sufferance warehouse until Health Canada clears.

Cold chain adds another layer. Most biologics and temperature-sensitive generics require 2-8°C storage from border crossing to final delivery. If your US supplier ships by truck to Montreal, that’s 8-12 hours in transit during summer heat. We work with FENGYE LOGISTICS on the sufferance warehouse side to maintain cold chain integrity during CBSA exam holds, but the importer is still responsible for documenting temperature logs on the CAD if Health Canada asks.

Under CARM Phase 2 Release 3 (live since May 2024), temperature excursion data is now part of the electronic release file. If the carrier’s reefer unit logs a deviation, expect CBSA to hold the shipment for Health Canada review before release.

Drawback claims and tariff mitigation

If you’ve already landed pharmaceutical shipments under MFN duty because CUSMA origin wasn’t available at time of import, you have a four-year window under the Customs Act to file a duty drawback claim and recover overpaid duties. The new US tariff environment makes drawback filings more attractive, especially if your US supplier can now provide retroactive CUSMA certificates after re-sourcing APIs from Mexico.

The catch: CBSA’s drawback program under CARM requires you to prove the goods qualified for preferential treatment at the time of original import, not just that they would qualify today. That means locking down manufacturing records, supplier declarations, and logistics documentation from the original shipment. Most importers don’t keep that level of detail past 12 months, which is why drawback claims have a sub-30% approval rate in pharmaceutical categories.

If your customs broker isn’t logging origin documents in the CARM Client Portal at time of release, you’ve already lost the drawback window.

What to do now

CBSA expects importers filing high-volume pharmaceutical imports to run HS classification reviews at least annually. The new US tariff landscape is a forcing function to do that review now, before the next verification letter lands.

For pharmaceutical importers with multi-country supply chains, the safest move is to treat every US-sourced or US-transshipped shipment as a potential CBSA audit target and file CADs accordingly. Over-document on the front end, or pay for it on the back end in verification costs and delayed releases. We run origin certificate audits and D-memorandum classification reviews as part of compliance retainer work. Start the conversation.

Frequently Asked Questions

What HS codes do pharmaceutical imports fall under for Canadian customs?

Most generic pharmaceuticals import under HS headings 3003 (bulk medicaments) or 3004 (dosage-form medicaments). CBSA applies tariff treatment and origin rules per the Customs Tariff Act based on the 6-digit HS classification you declare on the CAD.

How long does CBSA have to verify a CUSMA origin claim on pharmaceutical imports?

CBSA has 30 days from the date of your CUSMA origin claim to issue a verification request under D11-4-2. If the origin certificate or supplier declaration fails verification, you’ll owe retroactive MFN duty plus interest and face potential AMPS penalties starting at $3,500 per Level 1 contravention for negligent claims.

Do pharmaceutical imports require Health Canada clearance before CBSA releases them?

Yes. Your CAD in the CARM Client Portal must include the correct Drug Identification Number (DIN) or Natural Product Number (NPN) before CBSA releases under the Food and Drugs Act. Missing or incorrect OGD data will hold your shipment even if you have an RPP bond posted.

What temperature range must cold chain pharmaceutical imports maintain during CBSA exam holds?

Most biologics and temperature-sensitive generics require 2-8°C storage. Under CARM Phase 2 Release 3 (live since May 2024), reefer temperature logs are part of the electronic release file, and deviations can trigger Health Canada review before release.

Can I recover duties paid at MFN rates if I later get a CUSMA origin certificate?

Possibly. The Customs Act allows a four-year window to file a duty drawback claim, but you must prove the goods qualified for CUSMA preferential treatment at the time of original import—not just that they would qualify today. Drawback approval rates in pharmaceutical categories are below 30% because most importers don’t retain the required manufacturing and logistics documentation past 12 months.

What happens if my US pharmaceutical supplier sources APIs from China or India?

API sourcing from non-CUSMA countries often fails the tariff-shift test under CUSMA origin rules, even if final formulation happens in the US or Mexico. If your supplier hasn’t updated their CUSMA origin certificate to reflect post-tariff supply chain changes, your CAD filing carries compliance risk and potential retroactive duty exposure.

Source: FreightWaves